Top

Published in:

01-06-2010 | Basic Neurosciences, Genetics and Immunology-Original Article

Cytoprotective effect of (−)-deprenyl, (−)desmethyl-deprenyl and (−)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells

Authors: B. Szende, G. Barna, Kálmán Magyar

Published in: Journal of Neural Transmission | Issue 6/2010

Abstract

Postulated cytoprotective action of (−)-deprenyl (D), (−)-desmethyl-deprenyl (DD) and (−)-deprenyl-N-oxide (DNO) on l-buthionine-(S,R)-sulfoximine (BSO) toxicity was investigated using in vitro cultures of serum-deprived A-2058 melanoma cells. BSO (10 μM/l) decreased viable cell number and mitotic rate, while increased the apoptotic index. D and both of its metabolites, given together with BSO in the concentration of 50 μM/l, mitigated cell loss and decreased the apoptotic ratio. DD was the most effective compound in decreasing apoptotic activity, while DNO stabilized the cell number on control level and increasing the ratio of mitotic cells above the only serum-deprived control. Surveillance on mitochondrial membrane stability and antioxidant properties may play an important role in these processes.

Carillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994) (−)-Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci 54:975–981CrossRef

Gong J, Traganos F, Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218(2):314–319CrossRefPubMed

Jain A, Mårtensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 88(5):1913–1917CrossRefPubMed

Magyar K, Szende B (2004) (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25(1–2):233–242CrossRefPubMed

Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szökő É (2004) Pharmacological aspects of (−)deprenyl. Curr Med Chem 11:2017–2031PubMed

Magyar K, Szatmáry I, Szebeni G, Lengyel J (2007) Pharmacokinetic studies of (−) deprenyl and some of its metabolites in mouse. J Neural Transm (Suppl 72):165–173

Mårtensson J, Jain A, Stole E, Frayer W, Auld PA, Meister A (1991) Inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxidative stress. Proc Natl Acad Sci USA 88(20):9360–9364CrossRefPubMed

Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51(2):155–194CrossRefPubMed

Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW (1998) Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther 284(2):700–706PubMed

Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6(6):542–544PubMed

Seniuk NA, Henderson JT, Tatton WG, Roder JC (1994) Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(−)-deprenyl. J Neurosci Res 37(2):278–286CrossRefPubMed

Sugiura M, Kato R (1977) Reduction of tertiary amine N-oxides by rat liver mitochondria. J Pharmacol Exp Ther 200:25–32PubMed

Szende B, Bokonyi G, Bocsi J, Kéri G, Tímár F, Magyar K (2001) Anti-apoptotic and apoptotic action of (−)-deprenyl and its metabolites. J Neural Transm 108(1):25–33CrossRefPubMed

Szökő É, Tábi T, Borbás T, Dalmadi B, Tihanyi K, Magyar K (2004a) Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Electrophoresis 25(16):2866–2875CrossRefPubMed

Szökő É, Tábi T, Halász AS, Pálfi M, Kalász H, Magyar K (2004b) Chiral characterization and quantification of deprenyl-N-oxide and other deprenyl metabolites in rat urine by capillary electrophoresis. Chromatographia Suppl 60:S245–S251

Tatton WG, Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (−)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47(Suppl 3):S171–S183PubMed

Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63(4):1572–1575PubMedCrossRef

Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, Tatton NA (2002) Propargylamines induce anti-apoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301(2):753–764CrossRefPubMed

Youdim MBH, Weinstock M (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 123:1081–1086CrossRefPubMed

Youdim MBH, Wadia A, Tatton W, Weinstock M (2006) The anti-parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939:450–458

Title: Cytoprotective effect of (−)-deprenyl, (−)desmethyl-deprenyl and (−)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells
Authors: B. Szende
G. Barna
Kálmán Magyar
Publication date: 01-06-2010
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 6/2010
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-010-0413-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cytoprotective effect of (−)-deprenyl, (−)desmethyl-deprenyl and (−)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Effects of pharmacological entopeduncular manipulations on idiopathic dystonia in the dt sz mutant hamster

Impact of psychostimulants and atomoxetine on the expression of 8-hydroxyguanine glycosylase 1 in human cells

On the role of P2X7 receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X7 receptor antagonist A-438079

Time course of changes in the concentrations of monoamines in the brain structures of pentylenetetrazole-kindled rats

Development of neural correlates of empathy from childhood to early adulthood: an fMRI study in boys and adult men

The sympathetic-vagal balance against endotoxemia